BTCY - Biotricity, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.0300
+0.1150 (+6.01%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.9150
Open1.9800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.7800 - 2.2100
52 Week Range0.2600 - 2.2100
Volume293,531
Avg. Volume127,018
Market Cap73.279M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2290
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Biotricity Files a 510(k) Application for its Advanced ECG Analysis Software

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has filed a 510(k) application for US FDA clearance for its next generation, advanced ECG analysis software. The Company anticipates receiving a clearance by end of May 2020. Biotricity’s new ECG Analysis Software is engineered to improve analysis and identify anomalies by parsing through data trends and pinpointing information from which actionable insights can be gleaned.

  • GlobeNewswire

    Emerging Markets Report : What’s the Big Buzz on Biotricity ?

    Unless you’re one of the few who closely monitor the emerging medical technology space, Biotricity might not sound all that familiar to you, and neither might the process of a 510(k) filing. Biotricity Inc. is a medical diagnostic and consumer healthcare tech company.

  • GlobeNewswire

    Emerging Markets Report: At the Precipice

    When we first published regarding medical diagnostic and consumer healthcare technology company Biotricity (BTCY) back in December, our focus was on the Company’s innovation and aspirations in the vast sensor market. Mighty Forbes makes a compelling argument as to how technology could revolutionize preventative medicine. Just last week the Company announced that it is finalizing its FDA filing for its next generation, advanced ECG analysis software with an expectation to file a 510(k) application with the US FDA by the end of February 2020.

  • GlobeNewswire

    Biotricity Prepares its Filing for a 510(k) Application for its Advanced ECG Analysis Software

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it is finalizing its FDA filing for its next generation, advanced ECG analysis software with an expectation to file a 510(k) clearance application with the US FDA by end of February 2020. The global remote patient monitoring market is expected to reach $1.8 billion by 2026, and with this growth comes the inevitable deluge of data that will threaten to inundate healthcare professionals with a surplus of information, much of which will be non-actionable biometric data, wasting valuable time and resources. Today, traditional ECG monitoring requires significant human oversight to review and sift through incoming patient data for the purposes of determining which data is actionable and relevant.

  • GlobeNewswire

    Biotricity Converts $1.8 Million of Private Investor Notes into Preferred Equity

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has converted approximately $1.8 million in debt investment from long-term private investors into its recent Preferred Equity transaction, bringing the cumulative total sold in this round to $7.8 million. This conversion further expands the company’s runway. This investment is another step for the company’s broader goal to gain a listing on a senior stock market exchange.

  • GlobeNewswire

    Emerging Markets Report: An Ounce of Prevention

    In the Emerging Markets Report we are by name alone  perpetually on the look-out for new game-changing market trends. The company’s emphasis is on preventative care and empowering the user to manage their own healthcare.

  • GlobeNewswire

    Biotricity Completes $6M Investment from Private Investor

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed a $6M investment from its long term Private Investor in the form of a Preferred Equity transaction. Under the terms of the deal, the Preferred Equity will have a 12% per annum return, with an option to convert into Common Stock after 2 years at a 15% discount to the stock price at the time of conversion. This capital infusion comes at an important time and is structured to allow the company to benefit from its execution, while reducing and delaying the dilutive impact of early conversion, since conversion occurs at a future price.

  • GlobeNewswire

    Biotricity Completes Development of its ECG Patch Platform

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed development of its ECG patch platform. An extension of the company’s award-winning Bioflux® device, Biopatch is ideal for patients with less complicated cardiac conditions. It provides wireless communication to enable real-time monitoring for patients who are either at risk for, or diagnosed with, certain cardiac issues.

  • GlobeNewswire

    Biotricity Shows Continued Growth in Core Revenue for Fiscal Q2

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced financial results for its fiscal second quarter ending on September 30, 2019. The company’s financial results reflect a strong growth trajectory and positive commercialization progress. Gross revenues for the three months which ended September 30, 2019, correspond to 87% of those of the entire previous fiscal year which ended on March 31, 2019.

  • GlobeNewswire

    Biotricity CEO Waqaas Al-Siddiq in Live Interview on FOX Business Network

    Biotricity Inc. (OTCQB: BTCY), today announced that its CEO and Founder Waqaas Al-Siddiq will be on The Claman Countdown airing on Fox Business Network (FBN) on Wednesday, September 11th at 3:15 PM EDT. Mr. Al-Siddiq will discuss the current economic climate and how the Chinese tariff affects small and growing medical device companies, and ultimately, US patients.

  • GlobeNewswire

    BiotricityReports Fiscal Q1 ResultsShowingA Strong Growth Trajectory

    After achieving FDA clearance, the Company’s first remote patient monitoring (RPM) solution, Bioflux, experienced a high adoption rate during its fiscal 2018 limited market release to anchor clinics. In the first three months of fiscal year 2019, the Company has transitioned to full US release, ramping up its small sales force and expanding its sales footprint to 11 key states, with plans to expand further. This shift has the potential to improve patient care and save additional lives while also saving significant healthcare costs.

  • Why single payer can help address health care's grey areas: Digital health execs
    Yahoo Finance

    Why single payer can help address health care's grey areas: Digital health execs

    Two digital health officials told Yahoo Finance recently that Medicare for All could help address some of the industry’s toughest challenges.

  • GlobeNewswire

    Biotricity CEO Waqaas Al-Siddiq in Live Interview on Yahoo Finance

    Biotricity Inc. (OTCQB: BTCY), today announced that its CEO and Founder Waqaas Al-Siddiq will be on Yahoo Finance’s On the Move show on Tuesday, August 20th, airing at 11:45 AM EDT. Mr. Al-Siddiq will discuss American healthcare coverage and how insurance plans, whether public or private, impact growing, start-up medical device companies. Currently, more than seven million patients benefit from remote monitoring and the use of connected medical devices, and nearly 1,800 hospitals in the US are using mobile applications to improve risk management and care quality.

  • GlobeNewswire

    Biotricity Audited Year-End Results Demonstrate Execution of Commercial Growth Plans

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed its 10-K filing for the fiscal year, which ended March 31, 2019. The increase in revenues reaffirms the Company’s positive commercialization progress. Increased Market Penetration: Without including future new device placements, revenue run rates for Biotricity’s current installed customer base are projected to deliver over $2 million in recurring technology fees over the next 12 months.

  • GlobeNewswire

    Biotricity Doubles Sales Force – Expands Device Fleet by 59%

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has  expanded its fleet of Bioflux devices to meet customer demand. “Our sales expansion is yielding results and we see a consistent increase in sales as a result of our anchor clients recommending us to other medical professionals,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. Long-term, we are a technology company with a pipeline of complimentary remote patient monitoring and pre-emptive diagnostic technologies that will allow us to leapfrog and build on our existing platform.

  • GlobeNewswire

    Biotricity Provides Fiscal Fourth Quarter Update: Sales Force Expansion to Fuel Growth

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided a progress report for its fiscal 2018 fourth quarter, which ended March 31, 2019. The company continues to execute its plans to grow its sales force, expand its geographic footprint, and reach more Americans with its life-saving technology. The company’s flagship product, Bioflux, was met with a high adoption rate in the clinical community throughout the soft launch of the past year, leading to positive customer feedback and steady re-order rates.

  • GlobeNewswire

    Biotricity Achieves Market Expansion in Two New States

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional states in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and is taking the opportunity to capitalize on its momentum and increase its regional footprint. The Company’s remote patient monitoring device Bioflux monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.

  • GlobeNewswire

    Biotricity Announces Expanded R&D Team for the Development of its Fetal/Maternal and Ambulatory Wellness Monitoring Systems

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to announce further buildout of its R&D team, with the engagement of the Biomedical Engineering Department at the University of Calgary. The expanded team will include a Biomedical Engineering (BME) fellow under Dr. Ferber, Director of Biomedical Engineering’s Human Performance Laboratory, who will explore and develop effective representations of both fetal/maternal heart rate variability (HRV) and electro-hysterography (labor contraction monitoring) in pregnancy.

  • GlobeNewswire

    Biotricity Achieves Significant Milestones for Both Fetal/Maternal and Ambulatory Wellness Monitoring Systems

    Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that it has achieved significant progress in their University of Calgary-based R & D program for their latest wellness monitoring systems. Clinical data collection has commenced for both its fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems. Dr. David Liepert, QA/QI and Safety Lead and Director for the University of Calgary Cumming School of Medicine Department of Anesthesia commented, “We could not be more excited to participate in developing both these non-invasive medical-grade ambulatory monitors, utilizing the amazing fidelity and mobility of the Bioflux system.